Andrew Spaventa - 01 Jun 2021 Form 4 Insider Report for Singular Genomics Systems, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Dalen Meeter, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Jun 2021
Net transactions value: +$3,047,334
Form type: 4
Filing time: 01 Jun 2021, 21:50:09 UTC
Previous filing: 26 May 2021
Next filing: 06 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OMIC	Common Stock	Conversion of derivative security		+715,884			715,884	01 Jun 2021	By Axon Holdings, LLC	F1, F2
transaction	OMIC	Common Stock	Conversion of derivative security	$3,047,334	+173,144	+24%	$17.60^*	889,028	01 Jun 2021	By Axon Holdings, LLC	F2, F3
holding	OMIC	Common Stock						4,613,571	01 Jun 2021	By The Andrew K. Spaventa Living Trust dated April 9, 2014

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OMIC	Series Seed Preferred Stock	Conversion of derivative security		-362,266	-100%		0	01 Jun 2021	Common Stock	362,266		By Axon Holdings, LLC	F1, F2
transaction	OMIC	Series A Preferred Stock	Conversion of derivative security		-201,155	-100%		0	01 Jun 2021	Common Stock	201,155		By Axon Holdings, LLC	F1, F2
transaction	OMIC	Series B Preferred Stock	Conversion of derivative security		-152,463	-100%		0	01 Jun 2021	Common Stock	152,463		By Axon Holdings, LLC	F1, F2
transaction	OMIC	Convertible Promissory Note	Conversion of derivative security		-173,144	-100%		0	01 Jun 2021	Common Stock	173,144		By Axon Holdings, LLC	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Immediately prior to the closing of the Issuer's initial public offering ("IPO"), each share of the Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
F2	The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC. and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. The holdings of Axon Holdings, LLC depicted above reflect applicable transfers and related transactions prior to the IPO from Axon Ventures X, LLC.
F3	Immediately prior to the closing of the Issuer's IPO, the Convertible Note automatically converted into shares of the Issuer's common stock at a conversion price of $17.60 per share.
F4	The maturity date of the Convertible Note is the earliest to occur of (1) February 25, 2023 and (2) an Event of Default as defined in the related Note Purchase Agreement.